Oracle Corp. Stock Falls 5.5%, Underperforms Peers

Dow Jones2026/10/08 20:34

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Oracle Corp. slid 5.5% to $135.69 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36. This was the stock's second consecutive day of losses. Oracle Corp. closed 57.9% short of its 52-week high of $322.54, which the company reached on October 16th. The stock underperformed when compared to some of its peers, as Microsoft Corp. fell 1.3% to $522.61, Alphabet Inc. Cl C fell 0.7% to $344.86, and Alphabet Inc. Cl A fell 0.63% to $348.29. Trading volume totaled 41.3 million, compared to the 50-day average of 29.5 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 08, 2026 16:34 ET (20:34 GMT)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Oracle Corp. slid 5.5% to $135.69 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.1% to 51,231.64 and the S&P 500 Index falling 0.5% to 7,765.36.

This was the stock's second consecutive day of losses.

Oracle Corp. closed 57.9% short of its 52-week high of $322.54, which the company reached on October 16th.

The stock underperformed when compared to some of its peers, as Microsoft Corp. fell 1.3% to $522.61, Alphabet Inc. Cl C fell 0.7% to $344.86, and Alphabet Inc. Cl A fell 0.63% to $348.29.

Trading volume totaled 41.3 million, compared to the 50-day average of 29.5 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 08, 2026 16:34 ET (20:34 GMT)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26